Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Scientists have taken a decisive step toward ending one of transplant medicine’s most stubborn bottlenecks: the need to match donor organs to a recipient’s blood type. By chemically reengineering a ...

As well as affecting your health, weight and energy levels, what you eat has consequences for your libido, with diet ...